Methods and compositions for treatment of preeclampsia
AssigneesChildren's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
InventorsJudah Folkman, Raghu Kalluri
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing or predicting a pregnancy related disease or disorder. The methods involve detection of 2-methoxyestradiol, or a precursor or metabolite thereof.
Claims33
A method for treating preeclampsia comprising administering to a pregnant subject in need thereof an effective amount of 2-methoxyestradiol (2-ME), or a pharmaceutically acceptable salt thereof.
A method for treating preeclampsia, comprising:
- a) determining the level of 2-methoxyestradiol in a biological sample from a pregnant subject and comparing said level to the level of 2-methoxyestradiol in a control, wherein said control is a predetermined standard from at least one non-preeclamptic subject at about the same stage of pregnancy as said pregnant subject;
- b) administering to said pregnant subject an amount of 2-methoxyestradiol, or a pharmaceutically acceptable salt thereof, sufficient to raise the level of 2-methoxyestradiol in a biological sample of said subject to a level that is about the same as the level of 2-methoxyestradiol in said control;
- and
- c) repeating steps a) and b) on a regular basis thereby maintaining the level of 2-methoxyestradiol in said subject at a level that is about the same as the level of 2-methoxyestradiol in the control.
A method for reducing placental hypoxia in a subject with preeclampsia comprising administering to the subject an effective amount of 2-methoxyestradiol (2-ME), or a pharmaceutically acceptable salt thereof, to thereby reduce placental hypoxia in the subject.
A method for reducing sFLT-1 in a subject with preeclampsia comprising administering to the subject an effective amount of 2-methoxyestradiol (2-ME), or a pharmaceutically acceptable salt thereof, to thereby reduce the sFLT-1 in the subject.
Dependencies are inferred from the claim text.